This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Sticks to Their Hold Rating for Smith & Nephew (SN)

Tipranks - Tipranks - Tue Jun 30, 4:36AM CDT

RBC Capital analyst Charles Weston maintained a Hold rating on Smith & Nephew today and set a price target of p1,350.00.

End of Quarter Sale - 70% Off

Weston covers the Healthcare sector, focusing on stocks such as PolyPeptide Group AG, Oxford BioMedica, and Oxford Nanopore Technologies PLC. According to TipRanks, Weston has an average return of -6.3% and a 36.68% success rate on recommended stocks.

In addition to RBC Capital, Smith & Nephew also received a Hold from Barclays’s Hassan Al-Wakeel in a report issued on June 26. However, on June 25, Goldman Sachs maintained a Buy rating on Smith & Nephew (LSE: SN).

See today’s best-performing stocks on TipRanks >>

Based on Smith & Nephew’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p3.31 billion and a net profit of p342.47 million. In comparison, last year the company earned a revenue of p2.98 billion and had a net profit of p198 million

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.

Read More on GB:SN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).